Receptor sites for complement and for immune complexes on human nonhemopoietic tumor cells
- 1 July 1979
- Vol. 44 (1) , 131-135
- https://doi.org/10.1002/1097-0142(197907)44:1<131::aid-cncr2820440123>3.0.co;2-#
Abstract
Tumor cells in primary cultures derived from 11 untreated nonhemopoietic cancer patients were reacted with specifically coated sheep erythrocytes. Rosette formation between tumor and indicator cells was assessed. Of the primary cultures, 8 reacted positively with Ig[immunoglobulin]G-coated (EA[erythrocyte-antibody]IgG) and with IgM-human complement [C] coated (EAIgMC or EAIgMC 4,3) sheep erythrocytes. EAIgG rosette formation in positive cultures ranged from 25-85%, and for EAIgMC/EAIgMC 4,3 reactivity ranged between 22-95%. Rosette formation with E (uncoated) and EAIgM was negligible. Human nonhemopoietic tumor cells may carry on their surface receptor sites for an IgG component of immune complexes and for human C. These receptor sites may be important in the host-tumor relationship.This publication has 26 references indexed in Scilit:
- Tumor-bound immunoglobulins. Evidence for thein vivo coating of tumor cells by potentially cytotoxic anti-tumor antibodiesInternational Journal of Cancer, 1976
- Humoral cytotoxicity in melanoma patients and its correlation with the extent and course of the diseaseInternational Journal of Cancer, 1975
- The Fc receptor on thymus-derived lymphocytes. I. Detection of a subpopulation of murine T lymphocytes bearing the Fc receptor.The Journal of Experimental Medicine, 1975
- Studies on the mechanism of phagocytosis. I. Requirements for circumferential attachment of particle-bound ligands to specific receptors on the macrophage plasma membrane.The Journal of Experimental Medicine, 1975
- FEEDBACK INHIBITION OF SPECIFICALLY SENSITIZED LYMPHOCYTESThe Journal of Experimental Medicine, 1974
- Separation of Viable from Non-Viable Tumor Cells Using Ficoll-Hypaque Density SolutionImmunological Communications, 1973
- Elution of “blocking factors” from human tumors, capable of abrogating tumor‐cell destruction by specifically immune lymphocytesInternational Journal of Cancer, 1972
- A RECEPTOR FOR ANTIBODY ON B LYMPHOCYTESThe Journal of Experimental Medicine, 1972
- ISOLATION OF A FRAGMENT (C3a) OF THE THIRD COMPONENT OF HUMAN COMPLEMENT CONTAINING ANAPHYLATOXIN AND CHEMOTACTIC ACTIVITY AND DESCRIPTION OF AN ANAPHYLATOXIN INACTIVATOR OF HUMAN SERUMThe Journal of Experimental Medicine, 1969
- RECEPTORS FOR COMPLEMENT ON LEUKOCYTESThe Journal of Experimental Medicine, 1968